What if there was a company that could potentially cure the World’s deadliest diseases like: Ebola, HIV, H5N1 Avian Flu, Smallpox, H1N1 Swine Flu, just to name a few.
Guess what, there just might be, and there’s clinical data to back it up and it’s already earned the coveted FDA “Breakthrough Device” designation, you just haven’t heard of it yet, until now.
Analysts and Health Organizations See BIG Things from Aethlon Medical Inc. (NASDAQ:AEMD) — Developers of the Hemopurifier®
The threat of deadly diseases is real, as there’s very likely an impending “Apocalyptic Pandemic” on the way; this is truly getting very serious. For example, according to The World Health Organization (WHO) the world is “grossly unprepared” for a virulent pandemic… that could kill up to 80 million people within just 36 hours. According to the World Bank, if the world were today to encounter equivalent to the 1918 Spanish Flu pandemic, it would cost around $3 trillion and wipe out almost 5% of the global economy in the process.
This is where companies like Aethlon Medical Inc. (NASDAQ:AEMD) come into play, and for traders like us, the timing couldn’t be any better. Continue reading below and we will show you how this could be the trade of the decade, with a Wall Street analyst report giving this company a target price of $45.00 / share, and be sure to watch the short video that explains everything.
One of the most intriguing solutions being presented in the fight against pandemics, is that of the advanced high-tech Hemopurifier® device — which has already earned a coveted FDA “Breakthrough Device” designation, and analysts have pegged with a 12-month stock price forecast more than 3,400% higher than it is today.
The device is developed by a relatively under-the-radar NASDAQ company: Aethlon Medical Inc. (NASDAQ:AEMD). Aethlon has not only secured Hemopurifier’s® FDA designation of “Breakthrough Device” for treating life-threatening viruses, but also for the treatment of individuals with advanced or metastatic cancer. The Hemopurifier is able to filter the blood like a water filter and remove viruses and cancer. This is a game changing treatment to non curable diseases that we have never seen before.
Given a stock price target of $45, and currently trading at less than $1.50, there is plenty of investment potential in play for Aethlon Medical Inc. (NASDAQ:AEMD)
Introducing Aethlon Medical Inc. (NASDAQ:AEMD)
Company – Aethlon Medical Inc.
Rating – BUY
Price Target – $45 USD / Share
Increase +/- = +3,400% (approx. from current price)
Watch the Video below, and you’ll see why shares of Aethlon Medical Inc. (NASDAQ:AEMD) are about to go viral on Wall Street
Now with Aethlon Medical Inc. (NASDAQ:AEMD) having recently closed its latest $5 Million Public Offering in Mid-December—at an over-market price of $1.50 per share—the company is currently cashed-up and ready to take on 2020.
Over the next 12 months, the company intends to use a portion of the net proceeds towards currently planned clinical trials for the Hemopurifier®.
So far the company is exceeding the analyst’s projections for sales, with its reported Q4 2019 blowing CNN BUSINESS Analysts’ expectations out of the water — exceeding median analyst forecasts by +33.33%.
MEET THE AETHLON HEMOPURIFIER®
Unveiled in 2014 the Aethlon Medical Inc. (NASDAQ:AEMD) through its Hemopurifier® has developed one of the most fascinating, patent-protected therapeutic devices in the world.
Not only was it was named as one of Time Magazine’s Top 25 Inventions and 11 Remarkable Health Advances from 2014, but it was also recognized by the National Cancer Institute and awarded a grant in 2018.
This unique blood purification device is a first-in-class therapeutic technology boasting TWO FDA Breakthrough designations, through multiple therapeutic targets: Viral Disease and Cancer.
It’s designed for the rapid depletion of circulating viruses and cancer promoting exosomes. In short, when no approved therapies can come to our rescue, the FDA believes the Hemopurifier® has the breakthrough capabilities to truly help us in our time of need.
The company has its regulatory house in order, including New CMO Qualified standing for its manufacturing, and IDA for Viral Indications Active, with expanded access protocol approval in both the US and Canada, and Oncology IDE approval received in October 2019.
TAKING ON INFECTIOUS DISEASES (ie. Ebola, Hep C, and HIV)
By developing medical countermeasures with broad-spectrum capabilities, Aethlon Medical Inc. (NASDAQ:AEMD) is valiantly supporting an initiative set by the US Department of Health and Human Services.
To date, Hemopurifier® therapy has been administered to individuals infected with Ebola virus, Hepatitis C virus (HCV) and the Human Immunodeficiency virus (HIV).
In the case of Ebola, it was through a “remarkable response” to the
Hemopurifier® therapy to a comatose patient (a Ugandan physician) with multiple organ failure at the time that led to the accolades given by Time Magazine.
After the treatment was administered, the patient was ceremoniously discharged from Frankfurt University Hospital in Germany.
His viral load prior to the administration of a single 6.5-hour Hemopurifier® treatment was measured at 400,000 virus copies per milliliter of blood (copies/ml).
Post-treatment viral load was measured at 1,000 copies/ml representing an astounding 99.75% reduction—which never again rose above that level.
Viral load became undetectable five days after therapy. The treatment was well tolerated with no adverse events reported. Additionally, a post-treatment elution protocol verified that 242 million Ebola viruses were captured within the Hemopurifier® during treatment.
Beyond human treatment experiences, pre-clinical Hemopurifier® studies have validated the broad-spectrum capture of numerous viral threats, including:
- Dengue and West Nile virus
- Vaccinia and Monkey pox
- models for human Smallpox infection
Specific to pandemic influenza threats, Aethlon has also validated the capture of H5N1 avian flu, H1N1 swine flu, and the reconstructed 1918 influenza virus, which represents a model for the strain of influenza that killed an estimated 50 million victims in 1918 and 1919.
In-vitro studies of other viral threats are also ongoing.
FIGHTING THE BATTLE AGAINST CANCER
Part of the communication system that conveys signals to near or distant target cells and reprograms their functions are what are known as “exosomes”.
Beyond their role in metastasis, researchers have also published mounting evidence that tumor-derived exosomes contribute to tumorigenesis (the formation of cancer), cancer progression, angiogenesis (creation of blood vessels to fuel tumor growth), immune evasion, and resistance to radiation and chemotherapeutic drugs.
Recent discoveries also reveal that exosomes may contribute to bacterial and viral pathogenesis, the progression of Alzheimer and Parkinson’s diseases, the spread of prion proteins, and numerous inflammatory conditions.
Since their size is like that of the deadly viruses that Hemopurifier® already targets, exosomes are efficiently targeted in the blood purification therapy.
Not currently addressed by oncology, Aethlon’s Hemopurifier® therapy works in clearing out the cancer-promoting exosomes, and is synergistic with chemotherapy, immunotherapy and targeted agents.
Since receiving its FDA “Breakthrough Device” designation, Hemopurifier® therapy has also earned the spotlight of its role of fighting cancer in cases of chemotherapy resistance, promotion of metastasis, and immune suppression.
Multiple potential clinical targets for Hemopurifier® therapy are:
- Head and neck
- Melanoma, etc
The potential for Hemopurifier® therapy comes with well characterized markets, development pathways and endpoints.
From a clinical standpoint, an Early Feasibility Study (EFS) in Head and Neck Cancer has been initiated.
Aethlon Medical Inc. (NASDAQ:AEMD) has already completed its Phase I contract with the National Cancer Institute (NCI), pertaining to “Device Strategy for Differential Isolation of Oncosomes and Non-Malignant Exosomes.”
The project has earned the company an ongoing NCI SBIER Grant, dealing with “The Hemopurifier Device for Targeted Removal of Breast Cancer Exosomes from the Blood Circulation.”
Phase II of the NCI SBIR Contract began in September of 2019. The project entails $1.8 million in funding over 2 years, and investigating “Technologies for Differential Isolation of Exosomes and Oncosomes”.
OVER 100 YEARS OF HEALTHCARE EXPERIENCE
Aethlon Medical Inc. (NASDAQ:AEMD) is led by a supremely qualified team of experts in the field, with a combined experience of more than 100 years in healthcare.
The company is helmed by Chief Executive Officer, Timothy C. Rodell, M.D., a Physician Scientist with more than 30 years of development experience. His career entails both public and private companies, and includes 3 IPOs in the United States and abroad. Dr. Rodell has overseen 10 products from bench through late stage clinical trials, and has raised over $300 million in domestic and foreign private and public financings. He is also a current member of the Board of Directors for GlobeImmune. Prior to GlobeImmune, Dr. Rodell was President and CEO at RxKinetix, Inc. and has held senior management positions at OXIS International Inc. and Cortech, Inc.
The company’s Board is led by Chairman Charles J. Fisher, Jr., M.D. Recognized as an academic and industry thought leader, Dr. Fisher specializes in sepsis and inflammation. He is currently the Head of Critical Care at Cleveland Clinic, and has served as a Senior Executive with Lilly, Abbott, and Cardiome.
The Management team is rounded out by Chief Financial Officer James B. Frakes. His nearly 30 years of public company experience includes multiple CFO roles, and success in investment banking and venture capital.
Heading up the company’s research is Director of Research, Annette Marleau, PhD. An expert in immunology, virology, and cell biology, Dr. Marleau formerly held academic research positions at the The Scripps Research Institute, and the University of Nebraska Medical Center.
She is joined by Senior Scientist, Michael Jacobs and Director, Quality Systems and Regulatory Affairs, Lisa M. Boswell. Jacobs comes with an extensive and diverse background in medical device product development and process improvement, whose research has led to multiple publications in peer-reviewed journals, including Elsevier and the Royal Society of Chemistry. Boswell brings over 15 years of experience in Quality Control, Quality Assurance and Regulatory Affairs in both the biopharmaceutical and medical device industries, including a recent time in the same role for ZOLL Data Systems, Inc.
Aethlon Medical Inc. (NASDAQ:AEMD) currently receives a BUY rating from accredited analysts recognized by CNN BUSINESS. The company’s proprietary technology is a a first-in-class therapeutic technology that through FDA recognition as a “Breakthrough Device” targets both deadly diseases (Ebola, Hep C, HIV, etc) and Cancer. Its Q4 2019 sales outpaced analyst predictions by a third, and its latest round of financing have the company cashed up for its planned activities in 2020.
7 POTENTIAL GAME CHANGERS FOR NEW INVESTORS OF Aethlon Medical Inc. (NASDAQ:AEMD)
- Analyst coverage featured on CNN Business gives Aethlon Medical a 12-Month target price of $45 — representing median increase of +3,400%
- Q4 2019 sales revenue exceeded analyst’s expectations by +33%
- Recent closing of $5 million financing gives company cash on hand for future development
- Led by Award Winning Management Team with over 100 years of Healthcare Experience
- Calls from World Bank and World Health Organization to triple global funding in the fight against deadly disease pandemic potential
- Recognized as one of the Top 25 Inventions by Time Magazine and awarded grants and contracts by National Cancer Institute
- Documented results of improving the health of a patient with Ebola, linked to treatment from proprietary Hemopurifier® therapy
2020 looks like it could be the year for Aethlon Medical Inc. (NASDAQ:AEMD), keep it on close watch for further developments on both sides (Market Activity & Corporate Developments)
Analyst Review Team
USA News Group
Subscribe to receive our free
Market Review Weekly
Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This publication is neither an offer nor a recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has not been paid any fee’s for Aethlon Medical advertising and digital media. There may be 3rd parties who may have shares of Aethlon Medical, and may liquidate their shares which could have a negative effect on the price of the stock. The owner/operator do however own shares of Aethlon Medical (AEMD) which were purchased in the open market, and will sell these shares in the open market commencing immediately with no further notice given. The simple fact that we own shares in Aethlon Medical constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. MIQ and its Directors, associates, partners also reserve the right to buy and sell, and will buy and sell shares of Aethlon Medical at any time hereafter without any further notice, so let this disclaimer serve as notice that all material disseminated by MIQ has not been approved by the above mentioned company; we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.